hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06358092, orgStudyIdInfo id: ZSSYXHNK2401, briefTitle: Two-dimensional Shear Wave Elastography for Assessment of Cirrhosis and Portal Hypertension, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Third Affiliated Hospital, Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: Exploring and establishing new non-invasive risk stratification techniques for portal hypertension based on E imaging technology for measuring liver and spleen stiffness is an urgent need in this field of research., conditionsModule conditions: Cirrhosis, Liver, conditions: Portal Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 112, type: ESTIMATED, armsInterventionsModule interventions name: Hepatic venous pressure gradient, interventions name: Two-Dimensional Shear Wave Elastography, outcomesModule primaryOutcomes measure: the diagnostic performance of liver and spleen stiffness by E imaging technology for clinically significant portal hypertension, secondaryOutcomes measure: the diagnostic performance of microvessel imaging of hepatic microcirculation by E imaging technology for clinically significant portal hypertension, secondaryOutcomes measure: the difference among left, middle and right hepatic venous pressure gradient, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06358079, orgStudyIdInfo id: 258, briefTitle: Re-infusion of Unwashed Shed Blood During Off-pump Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2026-03-30, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Damascus University, class: OTHER, descriptionModule briefSummary: To assess the efficacy and side-effects of re-infusion of unwashed shed blood during off-pump coronary artery surgery using a novel cardiotomy circuit., conditionsModule conditions: Coronary Artery Disease, conditions: Blood Transfusion Complication, conditions: Cardiovascular Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A prospective study involving patients undergoing off-pump coronary artery bypass surgery. Patients will be randomized to two groups; an isolated cardiotomy circuit for re-infusion of unwashed shed blood will be used in group (a) and the conventional no re-infusion technique will be used in group (b)., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Outcome assessor will be blinded to the group type when analyzing data, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Re-infusion of unwashed shed blood, outcomesModule primaryOutcomes measure: blood transfusion requirements, primaryOutcomes measure: inflammatory response, primaryOutcomes measure: alveolar/arterial oxygen pressure gradients, primaryOutcomes measure: cost-benefit, primaryOutcomes measure: Neuro-markers, primaryOutcomes measure: myocardial marker CK-MB, primaryOutcomes measure: myocardial marker troponin-I, primaryOutcomes measure: blood loss, primaryOutcomes measure: complement response, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Damascus University Cardiac Surgery Hospital, status: RECRUITING, city: Damascus, country: Syrian Arab Republic, contacts name: Mohammad Bashar Izzat, FRCS, role: CONTACT, phone: +963943240820, email: mbizzat@gmail.com, contacts name: Albaraa Bara, MD, role: CONTACT, phone: 0934206291, email: mbizzat@damascusuniversity.edu.sy, geoPoint lat: 33.5102, lon: 36.29128, hasResults: False
protocolSection identificationModule nctId: NCT06358066, orgStudyIdInfo id: self assembling peptides, briefTitle: The Remineralization of Early Enamel Caries in Permanent Teeth, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-06, primaryCompletionDateStruct date: 2024-10-06, completionDateStruct date: 2024-12-06, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: Evaluate clinically the remineralizing potential of self-assembling peptide ( P11-4) fluoride plus in early enamel carious lesions of permanent anterior teeth., conditionsModule conditions: White Spot Lesion, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: diagnodent, interventions name: ICDAS 2, outcomesModule primaryOutcomes measure: measurement of mineral contents of teeth with early carious lesions among 2 arms. quantitatively using the laser fluorescence DIAGNOdent and qualitatively using ICDAS II scoring system, secondaryOutcomes measure: measurement of mineral contents of teeth with early carious lesions among 2 arms. quantitatively using the laser fluorescence DIAGNOdent and qualitatively using ICDAS II scoring system, eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 14 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06358053, orgStudyIdInfo id: CRTE7A2-2302C, briefTitle: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2028-04-30, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Corregene Biotechnology Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection., conditionsModule conditions: Cervical Cancer, conditions: Anal Cancer, conditions: Head and Neck Cancers, conditions: Other Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: CRTE7A2-01 TCR-T cell therapy, outcomesModule primaryOutcomes measure: DLT, primaryOutcomes measure: RP2D, primaryOutcomes measure: cevents (SAEs)., secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Overall Survival(OS), otherOutcomes measure: Peripheral blood TCR-T cell copy number, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06358027, orgStudyIdInfo id: DokuzEU-ACC-BOtlu-01, briefTitle: Evaluation of the Effects of Different Ventilation Modes Used During Anesthesia Awakening on the Frequency of Postoperative Atelectasis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-04-21, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Dokuz Eylul University, class: OTHER, descriptionModule briefSummary: In our study, we aimed to detect atelectasis developing in patients undergoing surgery under general anesthesia using transthoracic lung ultrasonography and to investigate the effect of ventilation methods used during recovery from anesthesia on the formation of postoperative atelectasis., conditionsModule conditions: Atelectasis, Postoperative Pulmonary, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 278, type: ESTIMATED, armsInterventionsModule interventions name: lung ultrasound, outcomesModule primaryOutcomes measure: Modified Transthoracic Ultrasound Score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06358001, orgStudyIdInfo id: 21-07, briefTitle: EchoTip AcuCore Post-Market Clinical Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Cook Research Incorporated, class: INDUSTRY, descriptionModule briefSummary: The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore., conditionsModule conditions: Adenocarcinoma, conditions: Neuroendocrine Tumors, conditions: Hepatocellular Carcinoma, conditions: Cholangiocarcinoma, conditions: Malignant Lymphoma, conditions: Metastasis, conditions: Chronic Pancreatitis, conditions: Autoimmune Pancreatitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 183, type: ESTIMATED, armsInterventionsModule interventions name: EchoTip AcuCore, outcomesModule primaryOutcomes measure: Technical Success, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06357988, orgStudyIdInfo id: NCI-2024-01149, secondaryIdInfos id: NCI-2024-01149, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-T, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-T, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2016-02-24, primaryCompletionDateStruct date: 2024-11-04, completionDateStruct date: 2024-11-04, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well GDC-0449 (vismodegib) works for treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have a smoothened or patched 1 genetic mutation. Vismodegib is a type of medication called a hedgehog signaling pathway antagonist and works by blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells., conditionsModule conditions: Advanced Lymphoma, conditions: Advanced Malignant Solid Neoplasm, conditions: Hematopoietic and Lymphatic System Neoplasm, conditions: Refractory Lymphoma, conditions: Refractory Malignant Solid Neoplasm, conditions: Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Echocardiography, interventions name: Radionuclide Imaging, interventions name: Vismodegib, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression-free survival (PFS) rate, secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06357975, orgStudyIdInfo id: NCI-2024-01126, secondaryIdInfos id: NCI-2024-01126, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-C1, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-C1, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2016-05-30, primaryCompletionDateStruct date: 2024-11-15, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have MET gene amplification. Crizotinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow., conditionsModule conditions: Advanced Lymphoma, conditions: Advanced Malignant Solid Neoplasm, conditions: Refractory Lymphoma, conditions: Refractory Malignant Solid Neoplasm, conditions: Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Crizotinib, interventions name: Radiologic Examination, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression-free survival (PFS) rate, secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06357962, orgStudyIdInfo id: CSAPG-40, briefTitle: Semi-permanent Acupuncture Effect on Cervical Ripening, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Consorci Sanitari de l'Alt Penedès i Garraf, class: OTHER, descriptionModule briefSummary: Cervical ripening is a medical treatment that can cause physical or emotional discomfort in pregnant women and is not without risks. This is a pilot study to assess feasibility and calculate the number of participants necessary for a complete clinical trial. The aim is to evaluate whether acupuncture can reduce the need for treatment (cervical ripening) in pregnant women at low or intermediate risk. Participants will be divided into two groups: one group will receive acupuncture, and the other will receive a simulated treatment of acupuncture., conditionsModule conditions: Pregnancy Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Semi-permanent acupuncture, interventions name: Sham of semi-permanent acupuncture, outcomesModule primaryOutcomes measure: Pharmacological induction, secondaryOutcomes measure: Change on score of Bishop scale, secondaryOutcomes measure: Onset of spontaneous labor, secondaryOutcomes measure: Duration of induction period Duration of the induction period Duration of the induction period Duration of the induction period, secondaryOutcomes measure: Duration of labor period, secondaryOutcomes measure: Satisfaction of pregnants, eligibilityModule sex: FEMALE, maximumAge: 40 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Consorci Sanitari Alt Penedes i Garraf, city: Vilafranca Del Penedès, state: Barcelona, zip: 08720, country: Spain, contacts name: Gloria Villena, role: CONTACT, phone: +34 938180440, phoneExt: 43197, email: gvillena@csapg.cat, contacts name: Noemí Casaponsa, role: CONTACT, phone: +34 938960025, phoneExt: 43197, email: recerca@csapg.cat, geoPoint lat: 41.34618, lon: 1.69713, hasResults: False
protocolSection identificationModule nctId: NCT06357949, orgStudyIdInfo id: E2-23-3615, briefTitle: The Effectiveness of High-intensity Laser Therapy on Plantar Flexor Muscle Spasticity in Stroke Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Hitit University, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate the effectiveness of high-intensity laser therapy for treating plantar flexor muscle spasticity in subacute and chronic stroke patients, focusing on its impact on spasticity, joint range of motion, pain, muscle thickness, functional ambulation, and quality of life., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: High-intensity laser, interventions name: Sham laser, outcomesModule primaryOutcomes measure: 10-Meter Walk Test, secondaryOutcomes measure: Visual analogue scale for pain (VAS- pain), secondaryOutcomes measure: Modified Ashworth Scale, secondaryOutcomes measure: Joint Range of Motion (ROM) Measurement, secondaryOutcomes measure: Ultrasonography, secondaryOutcomes measure: Timed Up and Go test, secondaryOutcomes measure: Stroke Specific Quality of Life Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Gaziler Physical Therapy and Rehabilitation Training and Research Hospital, status: RECRUITING, city: Ankara, country: Turkey, contacts name: Tuğba Atan, role: CONTACT, phone: +90 312 2911000, phoneExt: 1414, email: tubaatan@gmail.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06357923, orgStudyIdInfo id: 23-PP-13, secondaryIdInfos id: 2024-A00321-46, type: OTHER, domain: ANSM, briefTitle: Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-05-02, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Nice, class: OTHER, descriptionModule briefSummary: Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1., conditionsModule conditions: Aging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: dosage, outcomesModule primaryOutcomes measure: Expression level of LAMP2 (protein and isoform A and B mRNA), secondaryOutcomes measure: Presence of mutation in the "Oncomin Myeloid Reasearch Assay" gene panel targeting approximately 40 Different genes, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chu de Nice, city: Nice, zip: 06003, country: France, contacts name: Andrea CICCONE, role: CONTACT, phone: 0492034702, email: ciccone.a@hu-nice.fr, contacts name: marion causeret, role: CONTACT, phone: 0492034702, email: causeret.m@chu-nice.fr, contacts name: Andrea CICCONE, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70313, lon: 7.26608, hasResults: False
protocolSection identificationModule nctId: NCT06357910, orgStudyIdInfo id: HM-EMMA-102, briefTitle: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-17, primaryCompletionDateStruct date: 2024-06-29, completionDateStruct date: 2024-06-29, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Hanmi Pharmaceutical Company Limited, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fed condition in healthy volunteers., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: HCP2303, interventions name: RLD2302, interventions name: RLD2102, outcomesModule primaryOutcomes measure: AUCt, primaryOutcomes measure: Cmax, secondaryOutcomes measure: AUCinf, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: t1/2, secondaryOutcomes measure: CL/F, secondaryOutcomes measure: Vd/F, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 54 Years, stdAges: ADULT, contactsLocationsModule locations facility: Jeonbuk University Hospital, city: Jeonju, state: Jeollabuk-do, country: Korea, Republic of, contacts name: Jin A Lee, Researcher, role: CONTACT, phone: 063-259-3550, contacts name: Min-gul Kim, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.82194, lon: 127.14889, hasResults: False